The internet is full of "GLP-1 exit plans." Before anyone sells you a plan, it helps to know what the research shows happens when the medication stops. Two well-designed trials answered that question directly, and their results are remarkably consistent.
The semaglutide data: STEP 1 extension
In the STEP 1 trial, adults with obesity took weekly semaglutide or placebo for 68 weeks. The semaglutide group lost an average of 17.3% of body weight, versus 2.0% on placebo. Then treatment stopped, and 327 participants were followed for another year.
By week 120, the semaglutide group had regained 11.6 percentage points — about two-thirds of what they'd lost. Their net loss from the very start was 5.6%. Most of the improvements in blood pressure, blood sugar and lipids also drifted back toward baseline.
The tirzepatide data: SURMOUNT-4
SURMOUNT-4 used a sharper design. All 670 participants took tirzepatide for 36 weeks and lost an average of 20.9%. They were then randomized: half kept going, half were switched to placebo without knowing it.
Over the next 52 weeks, the group that continued lost a further 5.5%. The placebo group regained 14.0%. Nearly 9 in 10 who continued kept at least 80% of their loss; fewer than 2 in 10 who stopped did.
Side by side
| STEP 1 Extension | SURMOUNT-4 | |
|---|---|---|
| Medication | Semaglutide | Tirzepatide |
| Loss on treatment | 17.3% (68 weeks) | 20.9% (36-week lead-in) |
| After stopping | +11.6 points regained in ~1 year | +14.0% regained in 52 weeks |
| Kept going instead | Not tested | Further 5.5% loss |
Why does the weight come back?
Researchers describe obesity as a chronic, relapsing condition. GLP-1 medicines act on appetite and satiety signaling while they're on board. When they're withdrawn, those signals return, and the body's own weight-defense mechanisms are still in place. The trials weren't designed to prove why — but the pattern mirrors what happens when other chronic-condition medicines stop.
What these trials don't tell you
- They didn't test structured tapering, lifestyle programs or switching to another compound after stopping.
- They studied adults with obesity, not people using GLP-1s for modest cosmetic weight loss.
- Some residual benefit persisted in STEP 1 (lipids, CRP, HbA1c stayed somewhat better than baseline).
That gap is exactly where "exit protocol" marketing lives. When someone claims a supplement or peptide stack prevents rebound, ask for the trial. In most cases there isn't one.
The best evidence says GLP-1 benefits largely depend on staying on treatment. Any decision about stopping, tapering or switching belongs in a conversation with your prescriber — with these numbers in hand.
Every weight-loss compound, profiled
FDA status, evidence level, and mechanism for every compound in the weight-loss category. One reference, no hype.
Get the Weight Loss & Metabolism Guide →Questions I get asked
Sources: STEP 1 extension, Wilding et al., Diabetes Obes Metab 2022 · SURMOUNT-4, Aronne et al., JAMA 2024